BioCryst Pharmaceuticals, Inc. (BCRX) Cash Flow Statement

The gap between net income and operating cash flow is most pronounced in Q1 2026, where a massive non-cash charge (likely the $703.1M COGS write-down) drove net income deeply negative while operating cash flow was only -$62.1M. In contrast, Q2 2026 shows OCF/NI of 1.33, indicating high earnings quality with cash conversion exceeding accrual income. Investors should monitor whether such one-time items recur, as they distort the underlying cash generation capability.

The trajectory shows a clear inflection: from negative FCF in early 2024 to consistently positive FCF since Q3 2025, with Q4 2025's $275.2M FCF boosted by a one-time milestone. Excluding that quarter, Q2 2026's $104.1M FCF on $218.3M revenue suggests sustainable cash generation, though the sustainability depends on Orladeyo's continued uptake and stable gross-to-net. The FCF margin of 47.7% is exceptional for biotech, but investors should verify that this is not inflated by non-recurring items.

The negligible capital expenditure relative to revenue (CapEx/Rev of 0.1-0.8%) indicates that BioCryst does not require significant fixed asset investment to scale Orladeyo, likely due to contract manufacturing. This low capital intensity is a key driver of the high FCF conversion, but it also implies that the company may face higher variable costs or supply chain risks if manufacturing partners need expansion. The minimal depreciation (under $1M per quarter) further underscores the asset-light nature, but investors should consider whether future pipeline investments will require higher capex.

The large negative working capital changes in Q1 2026 and Q1 2025 (both around -$60M to -$70M) suggest seasonal or milestone-related cash outflows, possibly due to inventory builds or receivable timing. In contrast, Q2 2026 shows a modest -$3.1M, indicating stabilization. This volatility complicates quarterly cash flow analysis, but the overall trend suggests that working capital is not a persistent drag on cash generation. Investors should monitor whether inventory builds align with actual demand, especially given the international launch of Orladeyo.

The absence of shareholder returns is typical for a growth-stage biotech, but the $489.5M acquisition outflow in Q1 2026 is notable, likely related to a royalty financing or business development deal. This deployment, combined with the low cash balance of $89.7M, suggests management is prioritizing strategic investments over returning capital. The lack of buybacks may indicate that management views the stock as undervalued or that cash is needed for pipeline and debt service. Investors should assess the return on this acquisition, as it could either enhance or dilute shareholder value.

The cumulative gap between net income and operating cash flow is stark: net losses total -$468M while operating cash flow is positive $321M, driven by large non-cash items like SBC, depreciation, and the Q1 2026 inventory write-down. This divergence indicates that the company's underlying cash generation is stronger than GAAP earnings suggest, but it also raises questions about the sustainability of these adjustments. Investors should focus on cash flow as a more reliable indicator of economic performance, but must also consider that SBC (totaling over $200M in the period) is a real economic cost that dilutes shareholders.